Kraken tablets is offered in 2 variants: 25mg LGD 4033, 25mg YK-11 and 25mg S23, totaling 75mg per tablet for 20 tablets or 1500mg in total; and 25mg LGD 4033, 25mg YK-11 and 25mg S23, totaling 75mg per tablet for 40 tablets or 3000mg in total.
Ligandrol is a novel nonsteroidal oral selective androgen receptor modulator currently being investigated in research as a potential treatment for conditions relating to muscle dystrophy and osteoporosis.
Recent studies investigated the effects of LGD 4033 on muscle tissue in ovariectomized rats. A daily dose of LGD was administered and calculated according to body weight of each individual rat at the onset of the study. Results and changes were noted as soon as week 2, the control group having weighed significantly less than rats undergoing LGD treatment. This difference remained until the end of the study, irrespective of LGD treatments. Additionally, the LGD treatments resulted in a higher number of capillaries in all muscles studied. Longer randomized trials and research could potentially evaluate its efficacy in improving physical function and health outcomes in select populations.
|Molar Mass||338.253 g·mol−1|
A recent study has shown that YK11, a selective androgen receptor myostatin inhibitor, accelerates the expression of Follistatin in mice. Follistatin is a myostatin and activin-binding protein naturally found in the human body and has been used as a treatment for several degenerative muscle diseases. When follistatin levels are raised, myostatin levels will be inhibited. Inhibition of myostatin results in increased muscle mass and improved strength.
This study revealed that mice with low levels of myostatin have twice the amount of muscle mass compared to mice with high levels of myostatin. This shows the massive potential research implications of the strong anabolic effects that YK-11 can possess.
|Molar Mass||430.541 g·mol−1|
|IUPAC Name||methyl (2E)-2-[(8R,9S,10R,13S,14S,17S)-2′-methoxy-2′,13-dimethyl-3-oxospiro[1,2,6,7,8,9,10,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthrene-17,5′-1,3-dioxolane]-4′-ylidene]acetate|
According to the available studies, S23 induced infertility in all rats it was exposed to. These effects are dose-dependent and temporary, meaning the rats regained fertility following treatment. This shows potential of S23 as an oral male contraceptive.
According to the research, S23 subdues serum concentration of luteinizing hormone and follicle-stimulating hormone to produce biphasic effects on spermatogenesis. Additional research and clinical trials should be conducted to determine the efficacy and safety of S23 is as an oral contraceptive.
The above-mentioned study produced other beneficial desirable effects. For instance, researchers observed a stronger affinity to androgen receptors as compared to other popular compounds like Andarine. It also has an ideal anabolic-androgenic ratio allowing it to produce a good number of positive effects without any severe complications. One of those effects was increasing bone mineral density and lean muscle mass.
Therefore, while S23 may be effective as a male birth control pill, it can also be used for other purposes, especially among patients with chronic conditions that lead to muscle wasting.
|Molar Mass||416.76 g·mol−1|
By completing and paying for your order, you agree to our Terms and Conditions. Customer satisfaction is our number one priority, if you are not 100% satisfied with the product you received, please contact us at email@example.com